Chembio Diagnostics Inc.

NASDAQ:CEMI   1:43:00 PM EDT
5.08
+0.01 (+0.20%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)102.13M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.79 Million
Adjusted EPS-$0.28
See more estimates
10-Day MA$4.81
50-Day MA$4.73
200-Day MA$6.10
See more pivots

CHEMBIO DIAGNOSTICS, INC. Stock, NASDAQ:CEMI

3661 HORSEBLOCK ROAD, MEDFORD, NY 11763
United States of America
Phone: (631) 924-1135
Number of Employees: 295

Description

Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and syphilis; and a test for the detection of Hepatitis-C. Chembio Diagnostics, Inc. sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; and collaboration with an international diagnostics company to develop a POC diagnostic test for a specific type of cancer. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.